96
ɧ
102
ϋ
ܓ
ҁϓ
HCV genotype 2
ष
ݭ
ࣨაᅺۜʘႡ௪dᒗණ
ߕ
e
ߵ
eᅃe˚eɻʿҢ֜˙Ꮸ᜕
ዚeႡிᅀၾᑗґᏨ᜕ఊЗഃᐼ
ࠇ
6
10
ࡈ
ྼ᜕܃dਞၾ͉ᑘ
፬ʘყΝᅺ֛Ӻd
ࠈ
֛ᅺ
ۜዢ
ܓ
f
̬
102
ϋ
6
˜ᐏᒗਞ̋
2013
ϋୋ
ɖ֣˰
ߴޥޢ
ԭ
ݲ
ɽึdԨԭ
ݲ
อጳशषၾ
೯ߴޥ
࢝ᙄආБਖ਼ᕚစᑺdᑺᕚ
މ
Advancing regulatory
convergence in Asia with international standards
dႭҢ
၍ߴޥ
Փણ݄dԨ
ˢ༰Ңၾԭ
ݲ
ගʘࢨମd̋੶ਜਹ
ߴޥ
τΌ༟ৃʹ
ݴ
f
ʞ
102
ϋ
5
˜ਞၾ
ߕ
ᖹՊሙ๓ᕎ
ܓ
ʘଣሞʿ௰Գྼስᇖྼ୦dଉ
ɝᐝ༆
ߕ
ᖹՊ๓ᕎ
༊ܓ
᜕ʿঐ᜕ᗇ༊᜕lz࢙ᗫ༟ৃձ೯࢝dԨ
ܔ
ͭၾ
ყਖ਼ุ
USP
ᑺࢪʹ
ݴ
ၾሗूᆃdᄣ̋͊ԸʈЪʘпूf
ʬ৵ԸГԭሊ͛ᖹۜ၍Փ҅
National Pharmaceutical Control Bureau,
NPCB
102
ϋ
9
˜
ݼ
3
Τ֜ࡰЇ͉ટա
ߴޥ
Ꮸ᜕eҦஔᄲ
ݟ
ၾ
ݟ
ࣨഃ
ᗫྼਕᇖ
މ
ಂɧdಂග͉τર
ߴޥ
ҭϣᏨ᜕܆ᇙ׳БЪุʘྼή୦d
˸ʿεධ
ߴޥ
Ꮸ᜕ၾ͛
ي
ኪྼ᜕܃၍ଣၪᚐሙf
ɧeᔼᐕኜҿჯਹ
102
ϋ
9
˜
ࠌ
˚͉इဧ߱
Terumo
ᔼᐕኜҿႡிʈᅀeɧᔮᄃኜ
Mitutoyo
ʿ˚͉ყ᜕ᗇఊЗ
JFE Techno-Research
JFE-TEC
ආБᔼᐕኜҿᗫඎʿ᜕
ᗇҦஔʘʹ
ݴ
f୦Չண
၍ࠇ
ՓeႡிཀʿପۜʘτΌʿ̌ঐ༊ഃପۜᏨ᜕
ҦஔdϞпʺ͉ᔼᐕኜҿҦஔᄲ
ݟ
ʿପۜᏨ᜕ঐɢd̤̙ਂ
މ
ҢᏝᗫପ
ۜҦஔᇍeᏨਿʘਞϽf
ୋɧືcՇ֦ʹ
ݴ
ତ
ر
І
97
ϋ
11
˜
4
˚ऎࢠՇ֦ۜτΌᙄᖦ˸Ըd͉ӊϋၾ˙̜කɓ
ϣऎࢠՇ֦ۜτΌุਕ˴၍
ژ
ਖ਼ึᙄʿऎࢠՇ֦ۜτΌᙄ
-
ආ̈ɹ
ۜτΌึᙄdఱۜᅺeࠬᎈ๖ஷഃᙄᕚආБʹ
ݴ
fᔼᖹۜʱdᕐ˙
99
ϋ
12
˜
21
˚ᖦऎࢠՇ֦ᔼᖹሊ͛ΥЪᙄ
ܝ
уଡ଼Շ֦ᔼᖹۜτΌ၍ଣʿ
೯ʈЪଡ଼d࢝ක֛ಂʈЪʹ
ݴ
ྡ
10-2
f
ᕐ˙Աᙄ
ܔ
ܼͭ̍ۜeᖹۜeᔼᐕኜҿeੰۜʿʷ㛭ۜഃʞɽᗳପۜٙ
ٜટᑌᖩɹdஷజʔԄԫ
א
ࠠɽԫdԨΝ
ܔ
ͭၽᝄੰۜāɽ
ڭ
2013
ϋყ
ߴޥ
Ꮸ᜕ʿ೯อҦஔყীึ